Eliem Therapeutics (NASDAQ:ELYM) Trading Down 6.8% - What's Next?

Key Points

• Shares fell 6.8% to $6.54 on Tuesday (intraday low $6.475) with 307,447 shares traded, about 37% below the average daily volume of 486,688.
• The stock trades around its 50‑day SMA ($6.05) and well above its 200‑day SMA ($3.83), has a market cap of about $194.6M and a negative P/E of -12.34, signaling it is currently unprofitable.
• Eliem is a clinical‑stage biotech focused on CNS peptide and small‑molecule therapies, with lead program ELI‑200 being developed for spasticity and neuropathic pain after spinal cord injury.

Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report)'s stock price fell 6.8% on Tuesday . The stock traded as low as $6.4750 and last traded at $6.54. 307,447 shares traded hands during trading, a decline of 37% from the average session volume of 486,688 shares. The stock had previously closed at $7.02.

Eliem Therapeutics Stock Performance

The stock's 50 day simple moving average is $6.05 and its 200-day simple moving average is $3.83. The firm has a market cap of $194.58 million, a price-to-earnings ratio of -12.34 and a beta of -0.39.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company's scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.

The company's most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.